Cullin-RING ubiquitin ligases (CRLs) responsible for substrate specificity of ubiquitination play a key role in cell-cycle control and DNA damage response. In this study, we assessed associations between 16 599 SNPs in 115 CRL genes and lung cancer risk by using summary data of six published genome-wide association studies (GWASs) of 12 160 cases and 16 838 cases of European ancestry. As a result, we identified three independent SNPs in DCAF4 (rs117781739, rs12587742 and rs2240980) associated with lung cancer risk (odds ratio = 0.91, 1.09 and 1.09, respectively; 95% confidence interval = 0.88-0.95, 1.05-1.14 and 1.05-1.13, respectively; and P = 3.99 × 10 , respectively) after multiple comparison correction by a false discovery rate <0.05. Since SNP rs12587742 is located within the promoter region and one CpG island of DCAF4, we further performed in silico functional analyses and found that the rs12587742 variant A allele was associated with an increased mRNA expression (P = 2.20 × 10 −16 , 1.79 × 10 −13 and 0.001 in blood cells, normal lung tissues and tumor tissues of lung squamous carcinoma, respectively) and a decreased methylation status (P = 2.48 × 10 −9 and 0.032 in adipose and lung tumor tissues, respectively). Moreover, evidence from differential expression analyses further supported an oncogenic effect of DCAF4 on lung cancer, with higher mRNA levels in both lung squamous carcinoma and adenocarcinoma (P = 4.48 × 10 −11 and 1.22 × 10 −9
Introduction
Lung cancer is the most commonly diagnosed cancer and the leading cause of cancer deaths in the world. In USA, the estimated incidence of lung cancer in 2016 is 57.3 per 100 000 with an estimated mortality of 46 per 100 000 (1) . Etiology studies have revealed several environmental risk factors for lung cancer, such as exposures to cigarette smoke, radon, asbestos and arsenic (2) . Genetic factors such as heritable and somatic mutations are also involved in the etiology of lung cancer. Multiple genetic loci with moderate effects have also been reported by genomewide association studies (GWASs) of lung cancer at chromosome regions of 3q28, 5p15.33, 6p21.33, 6p22.1, 13q13.1, 15q25.1 and 22q12.1 in European populations (3) (4) (5) (6) (7) (8) . However, most of the published GWASs had mainly focused on single nucleotide polymorphism (SNPs) that reached genome-wide significance, most of which did not have clear biological functions (9) . In the post-GWAS era, identification of genetic variants with moderate but detectable effects and potential biological functions might provide additional insight about the complex mechanisms of cancer development. Currently, the availability of enormous genetic data made such studies feasible (8) .
Carcinogenesis is a multiple-step process that often involves loss control of cell proliferation. The ubiquitin-proteasome system is a major player in the regulation of critical cellular processes, including cell proliferation, differentiation and apoptosis. Dysfunction of the system has been implicated in several clinical disorders including inflammation and cancer (10, 11) . There are three types of enzymes that specifically mediate ubiquitin attachment to the target proteins: ubiquitinactivating enzymes (E1s), ubiquitin-conjugating enzymes (E2s) and ubiquitin ligases (E3s). In humans, there are only 2 E1s, at least 38 E2s and over 600 kinds of E3. Cullin-RING ubiquitin ligases (CRLs) represent one of the largest classes of E3 ubiquitin ligases mainly responsible for the substrate-specific ubiquitination. In addition, CRLs play a key role in cell-cycle control and DNA damage response (12) , and deregulation of CRLs may lead to abnormal cell proliferation and genomic instability, which in turn could result in malignance transformation. Currently, several components of CRLs (e.g. SKP2, CUL4A, CUL1 and RBX1/2) have been found to behave as oncogenes and are frequently amplified or overexpressed in human cancers, while several others (e.g. FBXW7 and VHL) act as suppressor genes for they were often mutated or inactivated in cancers (13) (14) (15) . Notably, as one of the most studied CRLs, SKP2 is found to be overexpressed and associated with aggressiveness and metastasis of non-small cell lung cancer, as a result of accelerated degradation of a cell-cycle inhibitor p27 (16, 17) . Moreover, largescale somatic mutations of KEAP1, another well-studied CRL, occurred in multiple human cancers, including non-small cell lung cancer (18) . According to the findings of these previous studies, we hypothesize that genetic variants with potential functions in genes encoding CRLs are associated with risk of lung cancer.
To test our hypothesis, we first performed a meta-analysis for SNPs in CRL-related genes by using summary statistics from six published lung cancer GWASs, including 12 160 cases and 16 838 controls from the TRICL-ILCCO Consortium (Transdisciplinary Research in Cancer of the Lung / the International Lung Cancer Consortium) (19) . For those identified SNPs as significant, we further performed stratified analysis by smoking status and histological types and investigated their effects on gene expression and methylation in cell lines and tissues by using the available genomic and genetic data from multiple public databases (e.g. TCGA and GTEx).
Materials and methods

Study populations
The study populations included in this study have been detailed in previous publications from TRICL and ILCCO (8, 19 (20, 21) . A written informed consent was obtained from each participant of each GWAS. The present study was approved by Duke University Health System Institutional Review Board and all methods performed in this study were in accordance with the relevant guidelines and regulations.
Genotyping platforms and quality controls
For all the GWAS datasets, multiple genotyping platforms were applied, including Illumina HumanHap 317, 317 + 240S, 370Duo, 550, 610 or 1M arrays (22) . For the meta-analyses, imputation was performed based on the reference data from the 1000 Genomes Project (phase I integrated release 3, March 2012) by using IMPUTE2 v2.1.1 (23), MaCH v1.0 (24) or minimac (version 2012.10.3) software. Only SNPs with an information score ≥ 0.40 in IMPUTE2 or an r 2 ≥ 0.30 in MaCH were included in the final analyses. Standard quality control on samples was performed on all scans, excluding individuals with a low call rate (<90%), extremely high or low heterozygosity (P < 1.0 × 10 −4 ) and non-European ancestry (using the HapMap phase II CEU, JPT/CHB and YRI populations as a reference).
Gene and SNP selection
The CRL-related genes were collected from the category of 'Cullin-RING ubiquitin ligase complex' in the Gene Ontology database (http://amigo. geneontology.org/amigo/term/GO:0031461). In total, we retrieved 118 genes from the database, 115 of which were located in autosomes (listed in Supplementary Table 1, available at Carcinogenesis Online). We then mapped all the SNPs located within 2 KB up-and down-stream of the NCBI Reference sequence of those selected genes and extracted their summary data from the GWAS datasets. SNPs included in the final metaanalysis were those with call rate ≥90%, minor allele frequency ≥1%, and P value for the Hardy-Weinberg Equilibrium test ≥10 -5 . All remained SNPs also passed the quality control of imputation with info ≥0.40 in IMPUTE2 or an r 2 ≥ 0.30 in MaCH. 
In silico functional analysis as a biological validation
Statistical methods
For each GWAS data set, we performed an unconditional logistic regression to estimate odds ratios (ORs) and 95% confidence intervals (CIs) per effect allele by using R (v2.6), Stata (v10, State College, TX, USA) and PLINK (v1.06) software with adjustment for the top significant principle components (8) . We performed meta-analysis by the inverse variance method using a fixed effects model (30) . If the Cochran's Q test P-value ≤ 0.100 or the heterogeneity statistic (I 2 ) ≥ 25%, a random-effects model was employed. We used the linear step-up method of Benjamini and Hochberg to calculate false discovery rate (FDR) with a cut-off value of 0.05 to correct for multiple comparisons (31) and used linear regression for the expression quantitative trait loci analysis and paired t-test for the gene differential expression analysis between tumor and adjacent normal tissues. For the differential expression and mRNA-methylation correlation analyses, outliers were defined as those outside the interval (Q1 −3×IQR, Q3 + 3×IQR) and were removed in the final analysis. Q1 and Q3 denote the first and third quartiles, respectively, and IQR denotes the interquartile range. Based on the 1000 Genomes European (EUR) reference data (phase I integrated release 3, March 2012), we used LocusZoom (32) and Haploview v4.2 (33) to construct the regional association plots and linkage disequilibrium (LD) plots, respectively. SNP pruning was applied, and SNPs with paired-wise r 2 < 0.30 were considered as independent. All other analyses were conducted with SAS (version 9.4; SAS Institute, Cary, NC, USA), if not mentioned specifically.
Results
Meta-analysis of the main effects
The sample sizes for the eight GWASs included in the present study are summarized in Supplementary Table 2, available at Carcinogenesis Online, and the workflow of this study is depicted in Figure 1 . We first performed meta-analysis using summary statistics from six GWASs (i.e. ICR, MDACC, IARC, NCI, Toronto and GLC) including 12 160 lung cancer cases and 16 838 noncancer controls. The overview of the overall association results is shown in the Manhattan plot ( Figure 2a ). We found there were 84 SNPs of 10 CRL-encoding genes with a nominal P < 0.001, 28 of which are in the DCAF4 gene with FDR < 0.05. More detailed information for each of the 84 SNPs (including position, effect allele, relative minor allelic frequency, effect sizes, unadjusted and FDR adjusted P-values, and heterogeneity test results) is summarized in Supplementary Table 3 , available at Carcinogenesis Online. The regional association plots ( Figure 2b ) demonstrated that the top SNP rs72734410 of DCAF4 was in moderate to high LD with other SNPs of the same gene but in very low LD (r 2 < 0.2) with the top SNP rs214278 in the neighboring gene PSEN1.
We then performed functional prediction for these 28 significant SNPs by using three bioinformatics tools (SNPinfo, regulomDB and HaploReg) and selected those apparently independent SNPs (paired-wise r 2 < 0.3) with potential effects on gene expression or functions for further analysis. As a result, two SNPs (rs17781739 and rs2240980) together with another functional SNP rs12587742 were chosen in further analysis (Figure 2c-e). As shown in Table 1 , SNP rs17781739 G>T was associated with a significantly decreased risk of lung cancer [odds ratio (OR) = 0.91, 95% confidence interval (CI) = 0.88-0.95, P = 3.99 × 10
-6 ], while two other SNPs in moderate LD (pair-wise r 2 = 0.38) were associated with a significantly increased lung cancer risk (rs12587742 G>A: OR = 1.09, 95% CI = 1.05-1.14, P = 4.97 × 10 -5 ; and rs2240980 C>G: OR = 1.09, 95% CI = 1.05-1.13, P = 1.44 × 10 -5 ). There was no heterogeneity observed for the effect estimates of these three SNPs from the six GWASs (Table 1 ). We then expanded the meta-analysis for these three identified SNPs by including two additional GWASs with European descents from Harvard University (984 cases and 970 controls) and deCODE (1319 cases and 26 380 controls) as a population validation, and similar results were observed ( Table 2) .
Stratified analyses
As lung adenocarcinoma and squamous cell carcinoma may have different risk factors, we performed stratified analysis by these histological types. By using 4862 adenocarcinomas and 3897 squamous cell carcinomas from all the eight GWASs (Supplementary Table 1 , available at Carcinogenesis Online), we found that the effect of rs1258772 was more significant in squamous cell carcinomas (OR = 1.12, 95% CI = 1.05-1.20, P = 4.16 × 10 -4 ) than in adenocarcinomas (OR = 1.08, 95% CI = 1.02-1.15, P = 0.010), while SNP rs2240980 had more significant effects in adenocarcinomas (OR = 1.10, 95% CI = 1.04-1.15, P = 3.44 × 10 -4 ) than in squamous cell carcinomas (OR = 1.07, 95% CI = 1.01-1.13, P = 0.017) ( Table 2) . However, heterogeneity test showed that the effect difference between two histological strata was non-significant for both SNPs.
Cigarette smoking is one of the major risk factors for lung cancer and may interact with genetic factors. According to the currently available smoking data, study subjects were divided into two groups: ever smokers (defined as individuals having smoked at least 100 cigarettes in their lifetime) and never smokers. We performed stratified analysis by smoking status and found that only SNP rs17781739 had a significant effect in ever smokers (OR = 0.92, 95% CI = 0.88-0.96, P = 3.31 × 10 -4 ) ( Table 2 ). No significant association was observed in never smokers for all three SNPs, which might be due to a reduced sample size (731 never smokers). The forest plots of the overall and stratification results for these three SNPs are shown in Supplementary  Figure 1a -c, available at Carcinogenesis Online.
In silico functional validation
The three SNPs were predicted with potentials to influence mRNA transcription (Table 1 ; Figure 2d and e). According to experimental data (e.g. histone modification, DNase cluster, transcription factor binding, RNAseq) from the ENCODE project (Figure 2d ), we found that two SNPs (rs17781739 and rs12587742) are located within one CpG island with strong signals for active enhancer and promoter functions (indicated by DNase hypersensitivity and histone modification H3K27 acetylation, and H3K4 tri-methylation, respectively). Further transcription factor binding analysis (using the transcription factor ChIP-seq data) showed that rs12587742 is located at the c-MYC motif as shown by the position weight matrix (PWM) based Sequence Logo (Figure 2e) , and the allele difference might influence the binding activity of the transcription factor. SNP rs2240980 was also predicted to be located at a regulatory region with evidence from DNase cluster and transcription factor CHIP-seq data ( Figure 2d) .
As genotyping data for the three identified SNPs were not available in the TCGA database, we performed imputation for them by using the reference data from the 1000 Genomes project. Further expression quantitative trait loci and meQTL analyses were conducted for SNPs with high quality imputation. Only SNPs from patients with lung squamous carcinoma passed the imputation quality control (imputation info > 0.9) and were used in further SNP-expression/methylation correlation analysis. As shown in Fig 3a, d and g, all of those three SNPs had a significant correlation with the mRNA expression of DCAF4 in the blood cells from 373 Europeans individuals (P = 7.85 × 10 and 8.76 × 10 −6 for rs17781739, rs12587742 and rs2240980, respectively). When put all these three SNPs into the same regression model, only SNP rs1258772 and rs2240980 remained significant (P =0.208, 5.86 × 10 −25 and 0.003 for rs17781739, rs12587742 and rs2240980, respectively). These results suggest that two SNPs (rs1258772 and rs2240980) in DCAF4, particularly rs1258772, have an independent effect on the gene expression.
We also performed SNP and mRNA expression correlation analysis by using the expression data in tumor tissues from 182 lung squamous cell carcinomas from TCGA database (Figure 3b , e and h). Once again, only SNP rs12587742 showed a significant correlation with increased mRNA expression of DCAF4 The pooling results of the four NCI sub-studies: the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study (ATBC), the Cancer Prevention Study II Nutrition Cohort (CPS-II), the Environment and Genetics in Lung Cancer Etiology (EAGLE) and the Prostate, Lung, Colon, Ovary Screening Trial (PLCO). The detailed results for each sub-study were presented in Figure 3 .
(P = 0.001). Such correlation was also supported by the results from normal lung tissues (P = 1.79 × 10 −13
) ( Supplementary  Figure 2a , available at Carcinogenesis Online) as well as multiple other tissues (e.g. testis, skin, colon, esophagus, subcutaneous adipose, stomach, pancreas, breast and thyroid) based on the data from the GTEx project (Supplementary Table 4 , available at Carcinogenesis Online). Based on those results, the rs12587742 'A' allele was associated with an increased mRNA expression of DCAF4 in most tissues except for testis. Considering this SNP is located within one CpG island, we further explored its influence on the methylation status of DCAF4 by using the data from TCGA and the MuTHER project. We observed that the 'A' allele was associated with a decreased methylation status (beta value, which is defined as the ratio of methylated probe intensity and the sum of methylated and unmethylated probe intensities) in the tumor tissues from 157 lung squamous cell carcinomas (Figure 3f , P = 0.032) and the adipose tissues from 428 female twin-pairs (Supplementary Figure 2b, ) (34) . No significance was observed for two other SNPs (rs17781739 and rs2240980) to be associated with mRNA expression (Figure 3b and h) and methylation in the tumor tissues (Figure 3c and i) . However, it should be noted that two other SNPs (rs2302587 and rs9788482) that had a moderate to relatively high LD with rs17781739 and rs2240980 (r 2 = 0.73 and 0.43, respectively) showed a significant correlation with the methylation status in the adipose tissues from the female twinpairs ( Supplementary Figure 2c and d, available at Carcinogenesis Online).
Differential expression analyses revealed that the DCAF4 gene had higher mRNA expression in tumor tissues from 156 lung squamous cell carcinomas and 238 adenocarcinomas (P = 4.48 × 10 -11 and 1.22 × 10 -9 ) than in adjacent normal tissues (Figure 4a and b) . Results from other studies collected in the cancer microarray database Oncomine also showed some evidence for a high expression level of DCAF4 in lung adenocarcinomas than in the normal tissues ( Supplementary Figure 3a and b, available at Carcinogenesis Online). We also observed a significantly negative correlation between the DCAF4 methylation , respectively) (Figure 4c and d) , which suggests that a high methylation status may lead to a decrease in mRNA expression of DCAF4 in the target tissues.
We finally investigated the mutations of DCAF4 in lung tumor tissues by using the public available data from the database of the cBioPortal for Cancer Genomics (http://www.cbioportal.org). As shown in Supplementary Figure 4 , available at Carcinogenesis Online, this gene had low somatic mutation rates in both the lung adenocarcinoma (LUAD; mutation rate = 0.5% [ 
Discussion
In this study, we performed an extensive analysis for associations between SNPs in 115 CRL-related genes and lung cancer risk by combining the summary data of six GWASs from the TRICL-ILLCO consortium including 12 160 cases and 16 838 cases. Such a large sample size allowed us to identify novel susceptibility loci with some moderate effects, which would have been often omitted in previous single GWAS. As a result, we identified three independent, potentially functional DCAF4 SNPs (rs117781739, rs12587742 and rs2240980) that were significantly associated with lung cancer risk in European populations. Further functional prediction analyses using data from blood cells and tumor tissues from the LUSC database revealed that the rs12587742 variant A allele was associated with an increased mRNA expression and a decreased methylation status of DCAF4. In addition, higher mRNA expression level of DCAF4 was also observed in tumor tissues than in adjacent normal tissues from patients with lung squamous cell carcinoma and adenocarcinoma. Moreover, significantly negative correlations were also observed between methylation status and mRNA expression levels in both sub-types of lung cancer. Taken together, our results provide a strong case that this novel genetic variant in DCAF4 was associated with lung cancer risk possibly by decreasing gene methylation status that had led to an increased mRNA expression of DCAF4.
DCAF4, also known as WDR21, is located on chromosome region 14q24.3 and encodes a WD40 repeat protein that interacts with the CUL4 and DDB1 to form the CUL4A-DDB1-DCAF complex. This interaction suggests that DCAF4 may be involved in nucleotide excision repair (NER), since DDB1 is one key component of the NER pathway, and that the CUL4A-DDBs complex may regulate NER activity through ubiquitination of several NER components, e.g. DDB2, XPC and histone H2A at the damaged DNA sites (35, 36) . Considering that smoking is the major risk factor for lung cancer and that smoking caused DNA damage is mainly repaired by the NER pathway, the increased DCAF4 expression as a compensation to a high level of damage to DNA may not be sufficient for the NER activity and thus result in high risk of lung cancer. This may partly explain the underlying biological and molecular mechanisms for the observed associations. In addition, DCAF4 may also be involved in the regulation of the telomere pathway and influence the telomere length, which is associated with risk of many cancers (37) . Indeed, SNP rs2535913 in the DCAF4 gene was recently reported to be associated with a shorter leucocyte telomere length (38) . A shorter telomere length had been found to be associated with an increased risk of lung squamous carcinoma and a decreased risk of lung adenocarcinoma in one large population study (39) and one recent meta-analysis (40) . In this study, we found that the rs2535913 minor A allele (38) also showed a significant association with a decreased lung cancer risk (Supplementary Table 3 , available at Carcinogenesis Online) and a decreased DCAF4 expression in adipose tissue and blood cells (GTEx data not shown). This SNP was also in a high LD (r 2 = 0.78) with one identified functional SNP rs17781739. Although there is still no report about functions of DCAF4 on telomerase activity and telomere length, it is known that the DDB1 is involved in the regulation of telomerase expression via E2f1 (41, 42) and the telomerase inhibition through ubiquitination-mediated TERT protein degradation (43) . Thus, DCAF4 might indirectly influence telomerase activity and telomere length through interaction with DDB1 to inhibit the formation of other DDB1 complexes.
CRLs mediate the substrate-specific binding in the ubiquitination and play important roles in maintaining cellular protein homeostasis, which is especially critical for the lung, as the lung often experiences chronic or acute inflammation and frequent immune responses as well as DNA damage-repair responses induced by toxic or pathogenic exposures (24, 44, 45) . Previous studies have reported that multiple CRL-related genes have been associated with inflammatory response and lung cancer. In the present study, in addition to DCAF4, we also found genetic variants in nine other CRL-related genes (i.e. COMMD1, CUL5, CUL7, DCAF8, KCTD10, KLHL21, KLHL22, PARK2 and TRIM21) to be associated with lung cancer risk with FDR < 0.2. Most of these genes were reported as tumor suppressor genes and also involved in the inflammation regulation (46) (47) (48) (49) . Notably, PARK2 is well studied as a Parkinson disease gene located at a fragile region of chromosome 6, which is prone to breakage and rearrangement. Genetic changes in this region have been found in several types of tumors, including glioma, lung cancer, colorectal and ovarian cancer (49) . We also observed that SNPs in PARK2 are associated with lung cancer risk, which might provide some additional biological support for the connection between risks of cancer and Parkinson (49, 50) .
In this study, although we revealed associations between multiple genetic variants in DCAF4 and lung cancer risk and also provided functional evidence to support these associations, the exact biochemical and molecular mechanisms of the effects of those variants on DNA methylation and expression as well as possibly inflammation, DNA repair and telomere functions are still unclear. The associations between DCAF4 expression levels with telomerase activity and telomere length warrant additional experimental validation. Further biochemical studies are also required to reveal the hidden mechanisms, such as the role of DCAF4 in DNA repair. Although these identified variants only had a moderate effect on lung cancer risk, their joint effect might have driven the risk higher, which needs to be further explored in future association studies. In addition, as shown in the supplementary data, rs12587742 is significantly associated with DCAF4 mRNA levels in multiple tumor tissues, which implies this SNP might have a pleiotropic effect on cancer risk. This also needs to be clarified by future population studies across cancers.
In conclusion, the present study revealed one novel functional genetic variant rs12587742 in DCAF4, which is associated with a moderately increased lung cancer risk possibly by influencing its gene expression in normal and tumor tissues. We also provided multiple levels of evidence to support possible oncogenic effect of DCAF4. Our findings have provided new clues for future functional studies to investigate the roles of CRL-related genes in lung carcinogenesis. 
